<SEC-DOCUMENT>0001493152-21-017696.txt : 20210726
<SEC-HEADER>0001493152-21-017696.hdr.sgml : 20210726
<ACCEPTANCE-DATETIME>20210723213732
ACCESSION NUMBER:		0001493152-21-017696
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210423
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210726
DATE AS OF CHANGE:		20210723

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protagenic Therapeutics, Inc.\new
		CENTRAL INDEX KEY:			0001022899
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		IRS NUMBER:				061390025
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12555
		FILM NUMBER:		211112178

	BUSINESS ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010
		BUSINESS PHONE:		(212) 994-8200

	MAIL ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Atrinsic, Inc.
		DATE OF NAME CHANGE:	20090630

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NEW MOTION, INC.
		DATE OF NAME CHANGE:	20070504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MPLC, Inc.
		DATE OF NAME CHANGE:	20050608
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO SECTION 13 OR 15(d) OF THE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date
of Report (Date of Earliest Event Reported): <U>April 23, 2021 </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>PROTAGENIC
THERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of Company as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-51353</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06-1390025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction <BR>
    of incorporation)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
    <BR>
    File Number)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer <BR>
    Identification No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">149
    Fifth Avenue, Suite 500, New York, NY</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10010</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive
    offices) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">212-994-8200
    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Company&rsquo;s telephone
    number, including area code)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
    name or former address, if changed since last report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any
of the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications
    pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant
    to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications
    pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications
    pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 400; text-transform: none; letter-spacing: normal; word-spacing: 0px">Securities
registered pursuant to Section 12(b) of the Act:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 40%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    of each class</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading
    Symbol(s)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of each exchange on which registered</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protagenic
    Therapeutics, Inc. Common Stock</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PTIX</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protagenic
    Therapeutics, Inc. Common Stock Warrants</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PTIXW</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
7.01. Regulation FD.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company&rsquo;s press release announcing a change in the timeline of initiation of the clinical trial of its lead drug candidate, PT00114,
is furnished hereto as Exhibit 99.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this Form 8-K (including the Exhibit) shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities
Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;) or otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth
by specific referenced in such a filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
8.01. Other Events.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
review of the company&rsquo;s investigational new drug (IND) application filed on June 29, 2021, the U.S. Food and Drug Administration
has requested that the company provide clinical sites with ready-to-inject clinical vials rather than providing site pharmacies with
the drug substance to be formulated locally. The company is immediately implementing this required change. As a result of this development,
the company expects to refile its IND and commence patient enrollment in the fourth quarter of 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9.01. Financial Statements and Exhibits.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 0.6in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>
    No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release announcing a change in the timeline of initiation of the clinical trial of its lead drug candidate, PT00114, entitled &ldquo; <B>Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial</B>&rdquo;</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROTAGENIC
THERAPEUTICS, INC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    July 23, 2021</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Alexander K. Arrow</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexander
    K. Arrow</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><IMG SRC="ex99-1_1.jpg" ALT="" STYLE="height: 98px; width: 250px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-right: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Protagenic
Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
23, 2021 &mdash; NEW YORK &mdash; Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies
to treat stress-related neurologic disorders, today announced that upon reviewing its investigational new drug (IND) application filed
on June 29<SUP>th, </SUP>the U.S. Food and Drug Administration (FDA) has requested that Protagenic provide clinical sites with ready-to-inject
clinical vials rather than providing site pharmacies with drug substance to be formulated locally. Implementing this FDA guidance will
have the added benefit of Protagenic&rsquo;s control of the formulation of the final drug product. Protagenic is immediately implementing
this required change. As a result of this development, the company expects to refile its IND and commence patient enrollment in the 4<SUP>th
</SUP>quarter of 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Protagenic Therapeutics, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protagenic
Therapeutics, Inc. (Nasdaq: PTIX) is a pre-clinical biopharmaceutical company endeavoring to develop first-in-class neuro-active peptides
into human therapeutics to treat several stress related disorders. For more information, visit <U>http://www.protagenic.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws,
including statements regarding Protagenic Therapeutics&rsquo; product candidates and pre-clinical development and clinical trial plans
and activities. Forward-looking statements include words such as &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;intends,&rdquo;
&ldquo;plans,&rdquo; &ldquo;could,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates&rdquo; and similar expressions. These forward-looking
statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties
include, among others, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including
the additional capital which will be necessary to complete the pre-clinical testing and eventual clinical trials of our product candidates;
our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties
inherent in pre-clinical and clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect
the Company&rsquo;s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in
the regulatory landscape or the imposition of regulations that affect the Company&rsquo;s products; and the other factors described under
the Risk Factors section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission.. Protagenic
Therapeutics cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and Protagenic undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary
statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Analyst
Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexander
K. Arrow, MD, CFA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Financial Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">213-260-4342</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>alex.arrow@protagenic.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Media
Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
Carbonara</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hayden
IR</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(646)-755-7412</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>james@haydenir.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_1.jpg
<TEXT>
begin 644 ex99-1_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #! >L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 4M8$CZ/=I%CS'B*+DXY/
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ME'(>8[L?0=*W:\W#9?RRYJGW!3P]G>04445ZATA1110 4444 %%%% !1110
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MZ^8-<BDG\9:C##_K9+^14YQ\Q<@<T\NWGZ!F.T/4^G)9HH(FDFD2.-1EF=L
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M$$'Z'G\*Z[X/\>,W_P"O1_YK6_\ $GP!>W^K)JNB6AF>XXN8E(&&'1N?7O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
8* "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
